Author: oncologs.com

Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease. Important advances in recent years include doctors using genetic tests to look for specific mutations they can target

A metabolic ‘survival switch’ controlled by the stiffness of triple-negative breast tumours can significantly influence how successfully their cancerous cells spread to other organs, according to new findings from the Garvan Institute of Medical Research. Credit: Dr Elysse Filipe / Garvan Institute Softer tumours fuel

WEST LAFAYETTE, Ind. — The National Science Foundation has awarded a $275,000 Phase 1 Small Business Innovation Research (SBIR) grant to Amplified Sciences. The clinical-stage life sciences diagnostic company is developing tests for early, more accurate detection of challenging diseases, starting with pancreatic cancer. Credit: (Purdue

PRESS RELEASE Credit: SGO & The GOG Foundation, Inc. PRESS RELEASE Chicago, IL and Philadelphia, PA, USA, April 11, 2024: The Society of Gynecologic Oncology (SGO) and The GOG Foundation, Inc. (GOG-F) Launch BRIDGES 2.0 Research Initiative with support from the Foundation for Women’s Cancer

In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. But while immunotherapy drugs offer new treatment possibilities, only about 20% to 40% of patients respond to these treatments. The majority either don’t respond or develop drug resistance.

Scientists at Duke-NUS Medical School have uncovered why some pancreatic and colorectal cancers[1] fail to respond to Wnt inhibitors, a promising new class of cancer drugs currently under development for these cancers. Their discovery, published in Science Advances, not only offers a new cancer therapy

The meeting point of the stomach and esophagus, the so-called gastro-esophageal junction, is a region of the human body that is not well-suited to the modern lifestyle. Stress, alcohol, nicotine and severe obesity are often triggers for pathological changes to the mucosal membrane in this

Researchers have unveiled a microfluidic device that significantly improves the separation of tumor cells and clusters from malignant effusions. This novel technology promises to advance the diagnosis and treatment monitoring of cancer by enabling the high-throughput, continuous-flow ternary separation of single tumor cells, tumor cell

Laura Soucek, an ICREA Research Professor, Director of VHIO’s Experimental Therapeutics Program,  and Head of our Models of Cancer Therapies Group, has received a European Research Council (ERC) Advanced Grant to maximize the use of the first clinically viable MYC inhibitor. Credit: VHIO. Laura Soucek,

PLYMOUTH MEETING, PA [April 11, 2024] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted more than 1,700 oncology professionals during the NCCN 2024 Annual Conference on April 5-7. The yearly meeting includes opportunities for care providers to interact with world-renowned specialists